On May 27, 2015, James Gulley, M.D., Ph.D., and Ravi Madan, M.D., discussed some of the basic concepts of therapies that are designed to stimulate the immune system and treat patients with prostate cancer. They focused on immunotherapies that are FDA approved or in the late stages of clinical development for prostate cancer and discussed potential future roles of cancer immunotherapy, including data that suggest that immune therapies can be combined with other types of therapies. They also addressed when to use and not to use immunotherapy and provide data about what to expect clinically from this type of treatment.
This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This webinar was made possible by the generous support of Bavarian Nordic. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.